Evidence map›Paper›PMID 42236828›Full record

ReviewNPJ precision oncology2026

When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition.

Frédéric Thomas, Antoine M Dujon, Andriy Marusyk, James DeGregori, Alexandre Fontanella, Margaux Bieuville, Mario Campone, Pascal Pujol, Catherine Alix-Panabières, Laurent Lecam and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Frédéric ThomasCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France. frederic.thomas2@ird.fr.
Antoine M DujonCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Andriy MarusykDepartment of Cancer Physiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
James DeGregoriDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Alexandre FontanellaCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Margaux BieuvilleInstitute of Organismic and Molecular Evolution (iomE), Johannes Gutenberg-Universität, Mainz, Germany.
Mario CamponeInstitut de Cancérologie de l'Ouest-René Gauducheau, Centre de Recherche en Cancérologie, Saint Herblain, France.
Pascal PujolCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Catherine Alix-PanabièresCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Laurent LecamIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Benjamin RocheCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Matthieu LacroixIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Christophe HirtzIRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France.
Laurent PoulainInserm U1086 Anticipe et Plateforme ORGAPRED, Université de Caen Normandie,Centre de Lutte Contre le Cancer François Baclesse, Caen, France.
Jean-Pascal CappToulouse Biotechnology Institute, University of Toulouse, INSA, CNRS, INRAE, Toulouse, France.
Beata UjvariSchool of Life and Environmental Sciences, Deakin University, Waurn Ponds, VIC, Australia.
Jordan MelianiCREEC/CANECEV, MIVEGEC (CREES) Department, University of Montpellier, CNRS, IRD, Montpellier, France.
Robert NobleDepartment of Mathematics, City St George's, University of London, London, UK.
Aurora M Nedelcu *Department of Biology, University of New Brunswick, Fredericton, NB, Canada.
Robert Gatenby *Department of Cancer Physiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Funding

Agence Nationale de la Recherche EVOSEXCAN project (ANR-23-CE13-0007)Centre National de la Recherche Scientifique NAThe Hoffmann Family NA
6 · The paper itself

Abstract

Many cancer therapies achieve durable control without complete tumor eradication, suggesting that disrupting tumor organization may be more critical than killing cells. We propose that effective treatments converge by destabilizing the tumor's Group Phenotypic Composition (GPC), the functional and spatial organization of interacting cell populations. When this organization collapses, tumors lose coherence. This perspective provides a unifying framework for designing therapies targeting tumor-level dynamics rather than cell number alone.

Identifiers

PMID42236828
PMCPMC13538637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.